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It is generally accepted that corticotropin-releasing hormone (CRH) acts as the main coordinator of the central
response to stress. Stress or an abnormal response to stressors has been found to modify the evolution of skin
disorders, including psoriasis and atopic dermatitis. Nevertheless, the specific pathogenic role of stress remains
unknown in skin diseases. Interleukin (IL)-18, a member of the IL-1 family, is a key mediator of peripheral inﬂam-
mation and host defense responses, and is secreted by human keratinocytes. Here, we investigated the regulatory
effect of CRH on expression of IL-18 in skin keratinocytes. Exposure of HaCaT cells to CRH resulted in a reduction
of IL-18 mRNA transcripts and its production was in a concentration-dependent manner. In order to investigate
whether the mitogen-activated protein kinase (MAPK) signaling pathway is involved in the downregulation of IL-18
production, cells were pre-treated with SB203580, an inhibitor of p38 MAPK, prior to the addition of CRH. This pre-
treatment blocked the decrease in IL-18 production. In addition, CRH treatment induced rapid phosphorylation of
p38 MAPK. SB203580 were able to inhibit CRH-induced p38 MAPK phosphorylation. CRH also inhibited production
of IL-18 in human primary keratinocytes. These results suggest that CRH regulates IL-18 production through the
MAPK signaling pathway in human keratinocytes.
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Corticotropin-releasing hormone (CRH), a 41-amino-acid
neuropeptide, plays an important regulatory role as a
key mediator of the hypothalamic–pituitary–adrenal (HPA)
system response to stress (Chrousos and Gold, 1992; Slo-
minski and Wortsman, 2000). CRH secretion from the hypo-
thalamus is triggered by various stress stimuli that include
pro-inflammatory cytokines (interleukin (IL)-1, IL-6, and
tumor necrosis factor (TNF)-a). CRH is also produced lo-
cally in peripheral sites that include the skin to regulate local
homeostasis (Crofford et al, 1995; Slominski et al, 1999,
2001). Functional CRH receptors have been demonstrated
in both human primary and HaCaT keratinocytes. Activation
of CRH receptors type 1 (CHR-R1) by CRH in HaCaT cells
leads to cAMP activation and calcium-dependent transmis-
sion pathways. The biological effects of CRH have been
shown to include the inhibition of keratinocyte proliferation
and regulation of adhesion molecules and cytokines. (Slo-
minski et al, 2000; Pisarchik and Slominski, 2001; Quevedo
et al, 2001; Zbytek et al, 2002).
IL-18 has multiple and complicated functions, as it par-
ticipates in innate immunity and T helper type 1 (Th1)- and
Th2-mediated responses. IL-18, formerly called interferon
(IFN)-g-inducing factor, is a novel proinflammatory cytokine
related to the IL-1 family that is produced by Kupffer cells,
activated macrophages, keratinocytes, intestinal epithelial
cells, osteoblasts, and adrenal cortex cells. It plays an im-
portant role in the Th1 response to toxic shock and shares
functional similarities with IL-12 (Dinarello, 1999). The primary
functions of IL-18 include the induction of IFN-g in T cells and
natural killer cells (NK), upregulation of Th1 cytokines includ-
ing IL-2, granulocyte-macrophage colony-stimulating factor
(GM-CSF) and IFN-g, and stimulation of the proliferation of
activated T cells. IL-18 alone can stimulate Th2 cytokine
production as well as allergic inflammation (Nakanishi et al,
2001). As a proinflammatory cytokine, the overproduction of
IL-18 induces severe inflammatory disorders. Thus, it is im-
portant to study the regulation of IL-18 expression in con-
trolling the inflammatory response and maintaining the
balance of immune system function. Recently, it was report-
ed that IL-18 by keratinocytes might play an important role in
cutaneous inflammatory response (Mee et al, 2000).Abbreviations: CRH, corticorpin-releasing hormone; IL, interleukin
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In this study, we investigated whether the expression of
IL-18 is regulated by CRH on human HaCaT kerationocytes,
and we also examined the regulatory mechanism of IL-18
production by CRH.
Results
Effect of CRH on IL-18 production in HaCaT cells To
study the effect of CRH on IL-18 mRNA expression in Ha-
CaT cells, the cells were exposed to different concentra-
tions of CRH. Total RNA was extracted after 6 h and RT-
PCR and real-time RT-PCR for IL-18 were performed. IL-18
mRNA expression was significantly reduced by CRH (Fig 1A
and B). IL-18 production was measured from supernatants
of CRH-stimulated cultured HaCaT cells collected 24 h
after the exposure (Fig 1C). IL-18 basal secretion was
138.41  8.2 pg per mL. CRH at 10 nM inhibited IL-18 se-
cretion significantly, to 75.47  2.9 pg per mL, a 45.6% de-
cline. As shown in Fig 1, IL-18 mRNA expression and its
production were significantly reduced by CRH in a concen-
tration-dependent manner.
Effect of MAPK inhibitors on IL-18 expression p38
MAPK has been significantly implicated in the regulation
of the expression of several cytokines in human keratin-
ocytes (Henley et al, 2004). The observation that CRH treat-
ment leads to the inhibition of IL-18 expression prompted us
to examine whether or not MAPK signaling pathways par-
ticipate in the regulation of IL-18 expression. Initial studies
were performed to determine the effect of the p38 MAPK
inhibitor on mRNA transcription of IL-18. HaCaT cells were
treated with an inhibitor of p38 MAPK (SB203580) at a con-
centration of 10 mM for 2 h, prior to the addition of CRH and
the expression of IL-18 mRNA transcript was assessed. The
effect of the p38 MAPK inhibitor on IL-18 protein secretion
was also detected. As shown in Fig 2, pre-treatment of Ha-
CaT cells with SB203580 for 2 h before the addition of 10
nM CRH completely blocked the decrease in IL-18 mRNA
expression and its production.
In order to demonstrate the direct evidence of the ac-
tivation of p38 MAPK, HaCaT cells were treated with CRH
and the phosphorylation of p38 MAPK was analyzed by
immunoprecipitation and western blotting using anti-p38
MAPK antibodies. CRH induced a transient phosphorylation
of p38 MAPK (Fig 3). The maximal activation of p38 MAPK
by CRH was observed after 30 min (Fig 3A). Normalizing
with non-phosphorylated form of p38 MAPK confirmed that
CRH specifically altered p38 MAPK phosphorylation, but
not the expression levels. The p38 MAPK inhibitor
SB203580 at 10 mM inhibited CRH-induced phosphorylat-
ion of p38 MAPK (Fig 3B). These results indicate that CRH
downregulates IL-18 expression by the activation of the p38
MAPK pathway.
Effect of CRH on IL-18 production in human primary
keratinocytes We next asked whether CRH could regulate
IL-18 production in primary human epidermal keratinocytes
and human fibroblasts. As shown in Fig 4, IL-18 production
was significantly reduced by CRH treatment in human pri-
mary keratinocytes, whereas there was no effect in human
fibroblasts. These results suggest that inhibitory effects of
CRH on IL-18 production may be unique to keratinocytes.
Discussion
The expression of CRH and functional CRH receptors has
been reported in both human primary and HaCaT keratin-
ocytes. Activation of CRH and CRH receptors results in in-
creased cyclic adenosine monophosphate production,
cytosolic calcium flux, inhibition of proliferation, modifica-
tion of cell surface expression of adhesion molecules, and
production of cytokines (Quevedo et al, 2001; Zbytek et al,
2002). CRH profoundly influences the function of the im-
mune system indirectly, through the activation of the HPA
axis and sympathetic system, and directly, through the local
Figure1
Effects of corticotropin-releasing hormone (CRH) on the mRNA
expression and production of interleukin (IL)-18 in HaCaT keratin-
ocytes. HaCaT cells were harvested after CRH treatment for 6 h. Total
RNA was extracted, and IL-18 mRNA transcript levels were determined
by RT-PCR (A) and real-time RT-PCR (B). (C) Cells were treated with
indicated concentration of CRH for 24 h. Cell supernatants were col-
lected and then IL-18 concentration was measured by ELISA, each
performed in triplicate. Data are mean  SD (po0.05).
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modulatory actions on inflammatory responses (Chrousos,
1995; Elenkov et al, 1999). CRH through stimulation of
hypophyseal corticotrophs to produce corticotropin induc-
es the adrenal production of glucocorticoids that in turn
suppresses immune reactions. In recent years, neuropep-
tides, including CRH, were discovered not only in the cen-
tral nervous system (CNS) but also in the peripheral sites
including immune tissues and inflammatory sites through
paracrine or autocrine pathway (Karalis et al, 1991). Stress
and CRH influence Th1 and Th2 immune responses by
stimulating glucocorticoid, catecholamine, and peripheral
CRH secretion as well as by altering the production of the
key regulatory cytokines (e.g., IL-12, IFN-g, IL-2, IL-4, and
IL-10) and histamine (Elenkov et al, 1999). Epidemiological
and experimental studies suggest that stress and stress
hormones influence the development, course, and pathol-
ogy of certain allergic, autoimmune/inflammatory, infec-
tious, and neoplastic diseases, mainly by stimulating Th2
instead of Th1-type immune response, which means by
enhancing humoral and suppressing cellular immunity (Ra-
mirez et al, 1996; Elenkov et al, 1998).
The skin is exposed directly and permanently to multiple
physical, chemical, and biological stresses. Skin should be
able to respond immediately against these stressors and
reestablish tissue homeostasis. Atopic dermatitis, psoriasis,
and other inflammatory skin diseases are known to be ex-
acerbated by stress. It was reported that CRH stimulates
the proliferation of keratinocytes (Mitsuma et al, 2001). It
Figure 2
Effects of the P38 mitogen-acivated protein kinase (MAPK) inhib-
itor SB203580 on the reduction in interleukin (IL)-18 expression
induced corticotropin-releasing hormone (CRH) in HaCaT cells. (A)
HaCaT cells were stimulated with or without 10 nM CRH for 6 h after
treatment with SB203580 (10 mM) for 2 h. Total RNA was extracted, and
cDNA was synthesized for RT-PCR. (B) Cells were incubated with
SB203580 (10 mM) for 2 h prior to addition of CRH (10 nM). After cells
were harvested for 24 h, IL-18 concentration was measured by ELISA,
each performed in triplicate. Data are mean  SD (po0.05).
Figure 3
Effects of corticotropin-releasing hormone (CRH) on activation
of p38 mitogen-acivated protein kinase (MAPK) in HaCaT cells.
(A) HaCaT cells were treated with 10 nM of CRH for indicated time
periods. Phosphorylation of p38 MAPK was analyzed by immunopricip-
tation and western blot as described in Materials and Methods. (B) The
effect of SB203580 on CRH-induced p38 MAPK activation HaCaT cells
were incubated with SB203580 (10 mM) for 2 h prior to addition of CRH
(10 nM). After cells were harvested for 30 min, phosphorylation of p38
MAPK was analyzed by immunopriciptation and western blot.
Figure4
Effects of corticotropin-releasing hormone (CRH) on the produc-
tion of intereleukin (IL-18) in primary human epidermal keratin-
ocytes and human fibroblasts. (A) Primary human epidermal
keratinocytes were treated with CRH (10 nM) for 24 h. Cell supernat-
ants were collected and then IL-18 concentration was measured by
ELISA, each performed in triplicate. Data are mean  SD (po0.05).
(B) Human fibroblasts were treated with CRH (10 nM) for 24 h. Cell
supernatants were collected and then IL-18 concentration was meas-
ured by ELISA, each performed in triplicate.
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may indicate the possible correlation of the proliferation of
keratinocytes and the degree of stress. Therefore, activation
of the stress system, via the direct and indirect effects of
CRH, might affect the susceptibility of an individual to cer-
tain autoimmune, allergic, infectious, or neoplastic diseases
(Arbiser et al, 1999).
In this study, the effect of CRH on IL-18 production was
examined in HaCaT keratinocytes. Previously, Zbytek et al
demonstrated the regulation of inflammatory cytokines by
CRH in HaCaT cells. The production of IL-6 and IL-11 was
enhanced, whereas IL-1b expression was inhibited (Zbytek
et al, 2002). Since IL-18 shares structural features with IL-
1beta, we hypothesized that CRH might inhibit expression
of IL-18. Here, we report that exogenously added CRH in-
hibits production of IL-18. IL-18 functions primarily as an
IFN-g inducer and a promoter of Th1 responses in T cells. In
addition to activated macrophages or Kupffer cells, it has
been shown that epidermal keratinocytes produce IL-18,
suggesting the importance of IL-18 in the skin (Stoll et al,
1997). Indeed, Naik et al (1999) reported that release of
mature IL-18 permits keratinocytes to regulate IFN-g pro-
duction during cutaneous inflammatory responses and
thereby modulate the character of a variety of T cell-medi-
ated cutaneous disorders.
It was reported that p38 MAPK regulates the expression
of several cytokines. In addition, p38, a member of the
MAPK superfamily, is activated by various stimuli, including
proinflammatory cytokines (e.g., IL-1b and TNF-a), lip-
opolysaccharide, and various environmental stresses (heat,
osmotic stress, and ultraviolet irradiation). It has been dem-
onstrated that CRH and its related peptides can activate
extracellular signal-regulated protein kinase (ERK) and p38
MAPK in several cell types (Dermitzaki et al, 2002; Wang
et al, 2003). Recently, the activation of MAPK signaling
pathways was reported to induce the proliferation and re-
lease of TNF-a in cultured rat microglia (Wang et al, 2003).
We investigated whether or not p38 MAPK is involved in
regulating IL-18 production by CRH. Our results indicate
that CRH downregulates IL-18 expression by phosphor-
ylation of p38 MAPK.
In this study, it was found that CRH regulates the ex-
pression of IL-18 in the skin cells. This finding may provide
an insight into the pathophysiology of neuroinflammatory
skin diseases such as psoriasis and atopic dermatitis.
Materials and Methods
Cell culture Human epidermal keratinocytes were obtained from a
normal young female donor. Freshly isolated epidermal cells were
cultured in KBM (BioWhittaker, Heidelberg, Germany) with full
supplements (0.1 ng per mL human epidermal growth factor, 0.5 mg
per mL hydrocortisone, 5 mg per mL insulin, 7.5 mg per mL bovine
pituitary extract, 50 mg per mL gentamicin, 50 ng per mL amp-
hotericin-B, and 0.15 mM calcium) according to manufacturer’s
instruction. Human fibloblasts were obtained from the American
Type Culture collection (CRL-2097, Manassas, Virginia). Cells were
cultured in Eagle’s minimum essential medium with 10% heat-in-
activated fetal bovine serum. Human keratinocytes cell line HaCaT
was obtained from the ATCC. This cell line was used for the ex-
periments while in the log phase of growth. HaCaT cells were cul-
tured in RPMI 1640 (Gibco-BRL, Gaithersburg, Maryland) medium
supplemented with 2 mM L-glutamine, antibiotics (100 U per mL
penicillin G and 100 U per mL streptomycin), and 10% heat-
inactivated fetal bovine serum (FBS) (Gibco-BRL). All cells were
cultured at 371C in a humidified incubator containing 5% CO2.
Informed consent was obtained from all subjects. The study
protocol conformed to the guidelines of the 1975 Declaration
of Helsinki and was approved by our institution review board
(St. Mary’s Hospital and The Catholic University of Korea).
Treatment of cells with inhibitor The cells were seeded at a
density of 1  106 cells per 100 mm dishes. After 48 h, the cells
were washed with serum-free medium and then replaced with
media without FBS at least 24 h prior to the experiments. HaCaT
cells were pretreated with 10 mM SB203580 (Sigma, St. Louis,
Missouri), a p38 MAPK inhibitor, for 2 h in serum-free medium.
CRH (10 nM) was then added to the cells. Human CRH (Sigma)
was used.
RT-PCR After the experimental treatment, the total RNA was ex-
tracted from HaCaT cells using the EasyBlue reagent (iNtRON,
Songnam, Korea), according to the manufacturer’s instructions.
The reverse transcription of RNA to cDNA was performed using a
power cDNA synthesis kit (iNtRON). IL-18 primers were: forward,
50-AGGAATAAAGATGGCTGCTGAAC-30; reverse, 50-GCTCACCA-
CAACCTCTACC TCC-30. The PCR amplification process consisted
of 32 cycles of 951C for 1 min; 601C for 1min; and 721C for 45 s.
Human b-actin primers were: forward, 50-GGCCATCTCTTGCTC-
GAAGT-30; reverse, 50-GCCCAGAGCAAG AGAGGCAT-30. The PCR
amplification process consisted of 30 cycles of 941C for 30 s; 561C
for 30 s; and 721C for 1 min.
Real-time RT-PCR analysis Total RNA was isolated using RNA-
zolB (Tel test, Friendswood, Texas) from HaCaT cells. For RT-PCR
analysis, 2 mg of total RNA was transcribed with 0.5 mg of random
primer using reverse transcriptase (Promega, Madison, Wisconsin)
at 371C for 1 h. PCR for amplification of IL-18 was performed with
forward primer (50-ATGGCTGCTGAACCAGTAGAAG-30) and re-
verse primer (50-CAGCCATACCTCTAGGCTGGC-30). Each amplifi-
cation cycle consisted of 10 s of denaturation at 941C, 20 s of
annealing at 551C, 30 s of extension at 721C, which was performed
in a Rotor-Gene 3000 real-time cycler (Corbett Research, Sydney,
Australia). b-actin was used as the control in the comparative CT
method.
IL-18 ELISA The concentration of IL-18 in the culture supernatant
was measured by a commercially available ELISA (MBL Medical &
Biological Laboratories, Nagoya, Japan). After stimulation, culture
supernatants of cells were collected, and then added to coated
wells. After the addition of diluted biotinylated anti-IL-18 Ab to
the wells, they were incubated for 3 h at room temperature. After
washing four times with phosphate-buffered saline (PBS)-Tween
20 (pH 7.4), streptavidin–horseradish peroxidase (HRP)-conjugated
anti-human IL-18 Ab was added, and was incubated for an hour.
The wells were washed four times with PBS-Tween 20, and subst-
rate solution was added, which was incubated for an hour. Relative
absorbance was measured at 450 nm and the IL-18 concentration
was calculated using a standard curve. Each supernatant was
analyzed in triplicate.
Immunoprecipitation and western blot analysis After the pro-
cedures mentioned above, HaCaT cells were lysed with lysis buffer
containing 50mM Tris-HCl (pH 7.5), 1 mM EDTA, 1 mM EGTA, 150
mM NaCl, 1% Nonidet P-40, 0.1% sodium dodecylsulfate (SDS),
1 mM Na3VO4, 1 mg per mL leupeptin, and 1 mM freshly added
phenylmethylsulfonyl fluoride. The cell lysates were then incubated
with immobilized anti-phosphotyrosine monoclonal antibody (2 mg).
Immune complexes were collected using protein-A agarose beads.
After having them washed three times with lysis buffer, proteins
bound to the beads were solubilized in elution buffer, containing 1
M Tris (pH 6.8) and 0.1% SDS. Protein concentrations of the sam-
ples were determined by the method of Bradford, using bovine
serum albumin (BSA) as a standard (Bio-Rad Laboratories,
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Hercules, California). An equivalent amount of proteins were boiled
for 5 min and electrophoresed on a 10% SDS-polyacrylamide gel
(PAGE), which was then transferred onto nitrocellulose membranes
(Bio-Rad Laboratories). Following blocking with 5% non-fat milk,
the blots were washed and incubated with anti-p38 MAPK anti-
body overnight at 41C. Anti-phosphotyrosine monoclonal antibody
and anti-p38 MAPK antibody were obtained from SantaCruz Bio-
technology (California). The blots were washed and incubated with
HRP-conjugated secondary antibody for 1 h at room temperature.
The blots were visualized by an enhanced chemiluminescence
detection system (ECL Detection Kit, Amersham Biosciences, New
Jersey). For western blotting against p38, CRH-treated and un-
treated cells were lysed with lysis buffer containing 1% Nonidet
P-40, 0.5% sodium deoxycholate, 1.0% SDS, 1mM EDTA, 1 mM
EGTA, 1 mM sodium orthovanadate, 1 mM leupeptin, and 1 mM
phenylmethylsulfonyl fluoride in PBS (pH 7.4). Whole-cell lysates
were directly resolved within 10% SDS-PAGE and transferred to
nitrocellulose membranes, and incubated with anti-p38 kinase an-
tibody. The blots were processed using HRP-conjugated second-
ary antibody and enhanced chemiluminescence.
Statistical analysis The statistical significance was calculated by
the two-sample independent-groups t test. Mean differences were
considered to be significant when po0.05.
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